Roquefort Investments PLC (ROQ) - Total Liabilities
Based on the latest financial reports, Roquefort Investments PLC (ROQ) has total liabilities worth GBX909.12K GBX (≈ $110.61 USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Roquefort Investments PLC (ROQ) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Roquefort Investments PLC - Total Liabilities Trend (2021–2024)
This chart illustrates how Roquefort Investments PLC's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Roquefort Investments PLC total assets.
Roquefort Investments PLC Competitors by Total Liabilities
The table below lists competitors of Roquefort Investments PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zoo Digital Group Plc
LSE:ZOO
|
UK | GBX16.04 Million |
|
Adventure Box Technology AB
ST:ADVBOX
|
Sweden | Skr15.06 Million |
|
Altitude Group Plc
LSE:ALT
|
UK | GBX9.67 Million |
|
Oxurion NV
BR:OXUR
|
Belgium | €16.98 Million |
|
Northern Bear Plc
LSE:NTBR
|
UK | GBX18.63 Million |
|
Ratu Prabu Energi Tbk
JK:ARTI
|
Indonesia | Rp754.04 Billion |
|
Trustco Group Holdings
JSE:TTO
|
South Africa | ZAC2.63 Billion |
|
Sable Exploration and Mining Ltd
JSE:SXM
|
South Africa | ZAC6.20 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Roquefort Investments PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Roquefort Investments PLC's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Roquefort Investments PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Roquefort Investments PLC (2021–2024)
The table below shows the annual total liabilities of Roquefort Investments PLC from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX861.73K ≈ $104.85 |
+46.30% |
| 2023-12-31 | GBX589.02K ≈ $71.67 |
+4.89% |
| 2022-12-31 | GBX561.58K ≈ $68.33 |
+17.63% |
| 2021-12-31 | GBX477.43K ≈ $58.09 |
-- |
About Roquefort Investments PLC
Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy and toxicology studies, as well as orphan drug indication; Midkine RNA oligonucleotide therapeutics with nov… Read more